Wegovy pill 4 mg cash price rises to $199 a month as introductory rate ends

The cash price of the 4 mg Wegovy pill (oral semaglutide) rose from $149 to $199 a month on April 15, 2026, when Novo Nordisk's introductory price for that dose ended ^[1]. The 1.5 mg starter dose remained at $149 a month, and the 9 mg and 25 mg doses remained at $299 a month ^[1][2].

GoodRx announced on Jan. 5, 2026 that the newly FDA-approved Wegovy pill would be available at a cash price of $149 a month at more than 70,000 pharmacies through its platform ^[1]. The fine print of that announcement said the $149 price applied to the two lowest doses, 1.5 mg and 4 mg, through April 15, 2026, and that a $199 monthly cash price would then apply to the 4 mg dose ^[1]. GoodRx also said consumers would be able to connect with a licensed healthcare provider through its GoodRx for Weight Loss service to determine eligibility and obtain a prescription when appropriate ^[1].

Novo Nordisk's patient site, NovoCare, lists the same self-pay prices by dose: $149 a month for 1.5 mg, $199 for 4 mg, and $299 for 9 mg and 25 mg ^[2]. The site defines one month as one bottle of 30 tablets and states that eligibility and restrictions apply ^[2]. Novo Nordisk says it reserves the right to modify or cancel the program at any time ^[2].

Pricing for the Wegovy pen, which is used weekly, works differently. NovoCare lists a limited-time offer for patients new to the Wegovy savings offer or NovoCare Pharmacy: $199 a month for the first two months of the 0.25 mg and 0.5 mg pens, an offer it says runs through Dec. 31, 2026. After that, those doses and the 1 mg, 1.7 mg and 2.4 mg pens are listed at $349 a month, and the 7.2 mg HD pen at $399 a month ^[2]. People with commercial insurance are listed as paying as little as $25 a month, subject to a maximum savings of $100 a month; government beneficiaries are excluded ^[2].

Why it matters for patients

People paying cash for the 4 mg tablet now pay $50 more a month than they did during the introductory period ^[1]. The 1.5 mg dose stayed at $149 a month, and the two highest tablet doses stayed at $299 ^[1][2], so the size of a monthly bill depends on which dose a prescriber has set. Dose changes are a medical decision, and the sources do not say how often patients move between these price tiers or how many people use the cash-pay option at all.

Wegovy is also sold as a weekly injection with its own cash and insurance prices ^[2]. For people who use insurance rather than cash, the listed cost can be as low as $25 a month under the savings terms Novo Nordisk describes, but that route excludes government beneficiaries and caps total savings at $100 a month ^[2]. The self-pay prices carry their own eligibility rules, and the manufacturer can change them ^[2].

What happens next

GoodRx said the $149 price for the two lowest doses ran through April 15, 2026 ^[1]. NovoCare currently lists $149 for the 1.5 mg tablet with no end date shown ^[2], so whether that price will rise later has not been disclosed. The offer for patients new to the Wegovy pen savings program is scheduled to run through Dec. 31, 2026, after which the listed prices are $349 a month for the 0.25 mg through 2.4 mg pens and $399 for the 7.2 mg pen ^[2]. Novo Nordisk states that it can modify or cancel these programs at any time ^[2], so the listed prices are not guaranteed to hold.